Trial Profile
INFORM-2
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2010
Price :
$35
*
At a glance
- Drugs Danoprevir (Primary) ; Mericitabine (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms INFORM-2
- Sponsors Roche
- 19 Feb 2010 Status changed from planning to discontinued, according to a Pharmasset media release.
- 19 Nov 2009 New trial record.
- 03 Nov 2009 The projected initiation date for this trial is in the first quarter of 2010, according to information presented in a Pharmasset media release.